PE20231190A1 - Degradadores de moleculas pequenas de piperidinilo de helios y procedimientos de uso - Google Patents
Degradadores de moleculas pequenas de piperidinilo de helios y procedimientos de usoInfo
- Publication number
- PE20231190A1 PE20231190A1 PE2023001130A PE2023001130A PE20231190A1 PE 20231190 A1 PE20231190 A1 PE 20231190A1 PE 2023001130 A PE2023001130 A PE 2023001130A PE 2023001130 A PE2023001130 A PE 2023001130A PE 20231190 A1 PE20231190 A1 PE 20231190A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- group
- membered heterocycloalkyl
- hydrogen
- cycloalkyl
- Prior art date
Links
- -1 HELIO PIPERIDINYL SMALL MOLECULE Chemical class 0.000 title abstract 4
- 239000001064 degrader Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 125000004432 carbon atom Chemical group C* 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000003003 spiro group Chemical group 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 1
- 101000599037 Homo sapiens Zinc finger protein Helios Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100037796 Zinc finger protein Helios Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invencion se refiere a un compuesto que tiene la estructura de formula (I), o una sal, hidrato, estereoisomero o tautomero farmaceuticamente aceptable del mismo, en donde: R1a, R1b, R1a' y R1b' son independientemente hidrogeno o alquilo C1-C6, o R1a y R1a' junto con el mismo atomo de carbono al que estan unidos forman un grupo espiro cicloalquilo C3-C7 o un grupo heterocicloalquilo de 4 a 7 miembros, o R1a y R1a' cuando estan en diferentes atomos de carbono, junto con los atomos a los que estan unidos, forman un grupo cicloalquilo C3-C7 o un grupo heterocicloalquilo de 4 a 7 miembros, o R1b y R1b' forman un grupo espiro cicloalquilo C3-C7 o un grupo heterocicloalquilo de 4 a 7 miembros, en donde dichos alquilo, cicloalquilo o heterocicloalquilo estan opcionalmente sustituidos; R2 es hidrogeno, hidroxi, amino, ciano, halo, alquilo C1-C6 y haloalquilo C1-C6; R3 es hidrogeno, amino, hidroxilo, ciano, halogeno, alquilo C1-C6 y haloalquilo C1-C6, en donde el alquilo esta opcionalmente sustituido, o R3 y R4 o R2 y R3 junto con los atomos de carbono a los que estan unidos forman un grupo cicloalquilo C3-C7 o grupo heterocicloalquilo de 4 a 7 miembros; cada R4 y R4' son hidrogeno, hidroxilo, amino, ciano, halogeno, alquilo C1-C6, entre otros, o R4 y R4' juntos con el mismo atomo de carbono al que esta unidos forman un grupo espiro cicloalquilo C3-C7, un grupo heterocicloalquilo de 4 a 7 miembros, C=(O), arilo C6-C10, heteroarilo de 5 o 6 miembros, o R4 y R4' cuando estan en diferentes atomos de carbono, junto con los atomos a los que estan unidos, forman un grupo cicloalquilo C3-C7 o un grupo heterocicloalquilo de 4 a 7 miembros; R5 y R5' son hidrogeno, alquilo C1-C6, entre otros, opcionalmente sustituidos; R6 es un arilo o heteroarilo sustituidos, entre otros; n1 es 0 a 2. Son compuestos especificos los compuestos (1), (2), entre otros. Tambien se refiere a una composicion farmaceutica. Dichos compuestos son derivados de piperidinilo degradadores Helios (IKZF2), siendo utiles en el tratamiento del cancer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063092610P | 2020-10-16 | 2020-10-16 | |
| US202163153599P | 2021-02-25 | 2021-02-25 | |
| PCT/US2021/055186 WO2022081976A1 (en) | 2020-10-16 | 2021-10-15 | Piperidinyl small molecule degraders of helios and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231190A1 true PE20231190A1 (es) | 2023-08-15 |
Family
ID=81208657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001130A PE20231190A1 (es) | 2020-10-16 | 2021-10-15 | Degradadores de moleculas pequenas de piperidinilo de helios y procedimientos de uso |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240034723A1 (es) |
| EP (1) | EP4228651A4 (es) |
| JP (1) | JP2023545396A (es) |
| KR (1) | KR20230090318A (es) |
| AU (1) | AU2021361060A1 (es) |
| CA (1) | CA3192393A1 (es) |
| CL (1) | CL2023000655A1 (es) |
| CR (1) | CR20230143A (es) |
| DO (1) | DOP2023000072A (es) |
| IL (1) | IL301690A (es) |
| MX (1) | MX2023004149A (es) |
| PE (1) | PE20231190A1 (es) |
| WO (1) | WO2022081976A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20220234A (es) * | 2019-10-30 | 2022-07-19 | Dana Farber Cancer Inst Inc | Degradadores de moléculas pequeñas de helios y procedimientos de uso |
| WO2022046631A1 (en) | 2020-08-24 | 2022-03-03 | Gilead Sciences, Inc. | Phospholipid compounds and uses thereof |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| AU2022306297A1 (en) | 2021-07-09 | 2024-02-08 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
| CN118488948A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| CN116640122A (zh) * | 2022-02-16 | 2023-08-25 | 苏州国匡医药科技有限公司 | Ikzf2降解剂及包含其的药物组合物和用途 |
| WO2023178035A1 (en) | 2022-03-14 | 2023-09-21 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| JP2025509610A (ja) | 2022-03-17 | 2025-04-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用 |
| WO2024167999A1 (en) * | 2023-02-08 | 2024-08-15 | Celgene Corporation | Compounds and compositions for selective degradation of engineered proteins |
| WO2025011624A1 (en) * | 2023-07-11 | 2025-01-16 | Etern Biopharma (Shanghai) Co., Ltd. | Bifunctional compounds for androgen receptor degradation and methods of use |
| WO2025117881A1 (en) * | 2023-12-01 | 2025-06-05 | Casma Therapeutics, Inc. | Compounds and methods for inhibiting autophagy |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245178A1 (en) * | 2024-05-21 | 2025-11-27 | Innovo Therapeutics, Inc. | Pak4, cstf2, or cstf2t protein degraders, pharmaceutical compositions, and therapeutic applications |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI793151B (zh) * | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| JP7585034B2 (ja) * | 2017-10-18 | 2024-11-18 | ノバルティス アーゲー | 選択的タンパク質分解のための組成物及び方法 |
| CA3119526A1 (en) * | 2018-12-03 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of helios and methods of use |
| EP3897637A1 (en) * | 2018-12-20 | 2021-10-27 | Novartis AG | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| WO2020160192A1 (en) * | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| CN113490528B (zh) * | 2019-02-15 | 2024-12-03 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| CR20220234A (es) * | 2019-10-30 | 2022-07-19 | Dana Farber Cancer Inst Inc | Degradadores de moléculas pequeñas de helios y procedimientos de uso |
| KR20220100921A (ko) * | 2019-11-13 | 2022-07-18 | 아프리노이아 테라퓨틱스 리미티드 | 타우 단백질 응집체를 분해하기 위한 화합물 및 이의 용도 |
| PE20230114A1 (es) * | 2019-12-23 | 2023-01-27 | Shanghai Jemincare Pharmaceuticals Co Ltd | Metodo y aplicacion de preparacion de compuesto como agente de degradacion de proteinas |
| MX2022010685A (es) * | 2020-02-27 | 2022-09-23 | Novartis Ag | Metodos de produccion de celulas que expresan receptores de antigeno quimericos. |
-
2021
- 2021-10-15 JP JP2023520211A patent/JP2023545396A/ja active Pending
- 2021-10-15 PE PE2023001130A patent/PE20231190A1/es unknown
- 2021-10-15 KR KR1020237011252A patent/KR20230090318A/ko active Pending
- 2021-10-15 WO PCT/US2021/055186 patent/WO2022081976A1/en not_active Ceased
- 2021-10-15 US US18/031,077 patent/US20240034723A1/en active Pending
- 2021-10-15 CR CR20230143A patent/CR20230143A/es unknown
- 2021-10-15 IL IL301690A patent/IL301690A/en unknown
- 2021-10-15 EP EP21881175.0A patent/EP4228651A4/en active Pending
- 2021-10-15 MX MX2023004149A patent/MX2023004149A/es unknown
- 2021-10-15 AU AU2021361060A patent/AU2021361060A1/en active Pending
- 2021-10-15 CA CA3192393A patent/CA3192393A1/en active Pending
-
2023
- 2023-03-08 CL CL2023000655A patent/CL2023000655A1/es unknown
- 2023-04-12 DO DO2023000072A patent/DOP2023000072A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022081976A1 (en) | 2022-04-21 |
| KR20230090318A (ko) | 2023-06-21 |
| IL301690A (en) | 2023-05-01 |
| EP4228651A4 (en) | 2024-11-27 |
| AU2021361060A1 (en) | 2023-03-30 |
| MX2023004149A (es) | 2023-07-10 |
| CR20230143A (es) | 2023-07-28 |
| CA3192393A1 (en) | 2022-04-21 |
| JP2023545396A (ja) | 2023-10-30 |
| CL2023000655A1 (es) | 2023-08-11 |
| DOP2023000072A (es) | 2023-09-29 |
| EP4228651A1 (en) | 2023-08-23 |
| US20240034723A1 (en) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231190A1 (es) | Degradadores de moleculas pequenas de piperidinilo de helios y procedimientos de uso | |
| ES2681799T3 (es) | Derivados de purina 2,6-sustituidos y su uso en el tratamiento de trastornos proliferativos | |
| ES2564179T3 (es) | Derivados de 4-(p-quinonil)-2-hidroxibutanamida para tratamiento de enfermedades mitocondriales | |
| AR054809A1 (es) | Compuestos de amino -5-heteroarilo (5 miembros) imidazolona y su uso para la modulacion de la b- secretasa | |
| AR066562A1 (es) | Derivados de pirrol condensados; una formulacion farmaceutica en base al compuesto y su uso para preparar medicamentos | |
| PE20240687A1 (es) | Compuestos de indazol como inhibidores de cinasas | |
| PE20221457A1 (es) | Degradadores de moleculas pequenas de helios y procedimientos de uso | |
| AR037983A1 (es) | Derivados de pirido [2,1-a] isoquinolina | |
| AR046308A1 (es) | Derivados amida | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| AR070079A1 (es) | Derivados de morfolino pirimidina usados en enfermedades relacionadas con mtor quinasa y/o p13k | |
| CO6321130A2 (es) | Piridinas carboxamidas como inhibidores de la 11 beta-hsd1 | |
| AR065811A1 (es) | Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos. | |
| AR060050A1 (es) | Compuestos moduladores del receptor de s1p y uso de los mismos | |
| CO6251243A2 (es) | Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c | |
| AR061564A1 (es) | Derivados de isoindoles, composiciones farmaceuticas y usos | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| PE20250759A1 (es) | Conjugado de anticuerpo bispecifico-farmaco de camptotecina y uso farmaceutico de este | |
| AR076235A1 (es) | Compuestos organicos y sus usos | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| PE20070491A1 (es) | Compuestos derivados de 9-azabiciclo[3.3.1]nonano como inhibidores de la recaptacion de neurotransmisores de monoamina | |
| AR036327A1 (es) | Compuestos derivados del cromano para uso terapeutico, composicion farmaceutica, uso de estos compuestos para la preparacion de medicamentos para tratar migrana, compuestos relacionados, y procesos para preparar esos compuestos relacionados | |
| AR072809A1 (es) | Compuesto de (3- piridinilcarbonil)-4-(fenilsulfonilpiperazina ), su uso para la elaboracion de unmedicamento para el tratamiento del dolor y composicion farmaceutica que lo comprende | |
| AR087771A1 (es) | Moduladores de la pde10 |